COVID-19 and MS disease-modifying therapies
نویسندگان
چکیده
منابع مشابه
Emerging oral disease-modifying therapies
Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...
متن کاملObesity and Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection that was first reported on December 31, 2019 in China . This disease behaves variously: from asymptomatic infection to influenza-like symptoms and severe acute respiratory distress syndrome (ARDS) . In the recent months, COVID-19 has infected millions and killed hundre...
متن کاملMultiple sclerosis and disease-modifying therapies.
Mia T. Minen, MD Steven Karceski, MD Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (DMTs) have been developed. These therapies are designed to decrease the number of MS attacks, and to slow the progression of the disease. They have become a standard part of the current treatment for MS. There are different classes of the currently available DM...
متن کاملOral Disease-Modifying Therapies for Multiple Sclerosis
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2020
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000761